There does not appear to be a standard definition of bio89-100 use in clinical practice. To accurately understand how this medication is used and to make the best use of this treatment in future trials, it will be helpful to think about clinical practice and make an effort to report the clinical practice patterns of all healthcare providers and institutions.
The cause of NASH is not known, but this disease is likely associated with a complex interaction of genetic, environmental and host factors. It also appears as though this syndrome is multifactorial, with an unknown number of predisposing genetic mutations and an undefined number of environmental factors, either in the mother or the child. For some persons there are no identifiable triggers. It is possible that NASH is a genetically heterogenous (or genetically multifactorial) spectrum of similar diseases that exhibit a wide range of different clinical presentations.
There are approximately 50,000 new cases of nonalcoholic steatohepatitis a year in the United States. There will be a significant decline in this number if the goal of the U.S. Preventive Services Task Force is reached.
Weight changes have been identified as one of the earliest signs of nonalcoholic steatohepatitis, although the presence of NASH cannot be determined before ultrasonography demonstrates steatosis. Early signs of progressive hepatopathy may include lab abnormalities, insulin resistance and dyslipidemia. A key feature is unexplained anemia.
Although there was no significant correlation between disease severity and remission in our study, the results obtained are encouraging as they showed that NASH patients may be at high risk for remission.
Most nonalcoholics with NASH prefer conservative treatment, such as weight loss and nutritional and drug treatment. Surgery is an effective method of management if the cause is found to be fibrosis. Liver transplant is the only effective treatment for patients with liver cirrhosis who are unable to maintain a healthy weight.
Steatohepatitis occurs in all populations, affects males and females equally, and affects obese and nonobese persons equally effectively. The cause is an infectious agent that spreads to people with the predisposition to develop steatohepatitis-associated liver disease. The cause is currently unknown and the diagnosis is based on clinical and pathological findings. Further research is needed to discover the cause and discover a suitable treatment.
A substantial proportion (35%) of the eligible patients did not initiate treatment in clinical trials. The main barriers to inclusion in clinical trials were patient awareness of the disease, its treatment and prognosis, and low patient-physician association. Results from a recent clinical trial have implications for improving adherence to available treatment options for NASH.
Data from a recent study, to our knowledge, provide the first evidence of a heritable component to NASH. Identifying such a component is a prerequisite for development of preventive and therapeutic measures against this common and severe form of liver disease.
Bio89-100 is a promising serum biomarker for nonalcoholic steatohepatitis. To date, it is not possible to verify how predictive a single serum biomarker is of disease severity or response to treatment. However, prospective studies will be valuable in determining the diagnostic utility and therapeutic potential of this serum biomarker.
Many of the features of NASH are present in patients older than 40 years when they have metabolic syndrome. However, NASH progresses at a greater rate in younger age groups. NASH develops earlier in men than women. It is more common in people with metabolic syndrome and also in those with nonalcoholic fatty liver disease. Although NASH is not directly a risk factor of type 2 diabetes or cardiovascular disease, it may be related with metabolic syndrome by its link with lipids and insulin resistance.
If you are interested in hepatic surgery and nonalcoholic steatohepatitis you need to keep up to date on new guidelines and therapies. Several studies have been published which will assist you or your doctor on selecting the most effective therapy for your patient. You can also check your disease stage on the National Institutes of Health Web site by searching for ‘nonalcoholic steatohepatitis’. Results from a recent paper you see here and on NIH.gov give you the latest guidelines and can help you determine your best decision for your patient. Many trials also exist for a treatment for nonalcoholic steatohepatitis on the clinicaltrials.gov list.